SG190131A1 - Cosmetic composition containing an oleanolic acid - Google Patents
Cosmetic composition containing an oleanolic acid Download PDFInfo
- Publication number
- SG190131A1 SG190131A1 SG2013034087A SG2013034087A SG190131A1 SG 190131 A1 SG190131 A1 SG 190131A1 SG 2013034087 A SG2013034087 A SG 2013034087A SG 2013034087 A SG2013034087 A SG 2013034087A SG 190131 A1 SG190131 A1 SG 190131A1
- Authority
- SG
- Singapore
- Prior art keywords
- oleanolic acid
- cosmetic composition
- liposomes
- nano
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims abstract description 60
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title claims abstract description 60
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title claims abstract description 60
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 229940100243 oleanolic acid Drugs 0.000 title claims abstract description 60
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title claims abstract description 60
- 239000002537 cosmetic Substances 0.000 title claims abstract description 55
- 239000002502 liposome Substances 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 238000009472 formulation Methods 0.000 claims description 14
- 230000036570 collagen biosynthesis Effects 0.000 claims description 7
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 229920001436 collagen Polymers 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- 230000001153 anti-wrinkle effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 230000035807 sensation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- 239000006210 lotion Substances 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 235000010445 lecithin Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000008341 cosmetic lotion Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- -1 acyl glutamate Chemical compound 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001237728 Precis Species 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 229960001777 castor oil Drugs 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 241001414371 Staphylea holocarpa Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- IPVNPUHVCZJVOI-VJSFXXLFSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 IPVNPUHVCZJVOI-VJSFXXLFSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 229940080277 cholesteryl sulfate Drugs 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a solubilized cosmetic composition which uses an5 oleanolic acid entrapped in nano-liposomes as an active ingredient. The present invention can increase percutaneous absorption of an active ingredient using nano-liposomes to promote synthesis of collagen, thus providing a good anti-wrinkle effect. Also, since other additional raw materials are not used for capsulation, the manufacturing cost of a product can be reduced and a good sensation during use can be provided.10[No Figure]
Description
COSMETIC COMPOSITION CONTAINING AN OLEANOLIC ACID
The present invention relates to a solubilized cosmetic composition containing, as an active ingredient for reducing wrinkles, oleanolic acid encapsulated in nano-liposomes.
The skin is the primary barrier of the human body. It protects the organs from changes in temperature and humidity and from damage from the external environment, such as UV radiation or pollutants. It also plays an important role in homeostasis, for example, in regulating body temperature. However, excessive chemical and physical stimulation, stress, malnutrition and the like are harmful to the normal functions of the skin and accelerate skin aging phenomena, such as elasticity loss, keratinization and wrinkle formation. Cosmetic products, which have been used to prevent such phenomena and keep the skin healthy and elastic, have various problems in that they mostly have various problems insufficient effects or cause skin side effects (Korean Patent Laid-
Open Publication No. 10-2010-0064451).
Studies on raw materials having the effect of preventing skin aging without causing skin side effects have been actively conducted, and as a result, it was found that a skin cosmetic composition containing oleanolic acid exhibits an excellent effect of preventing skin aging.
Oleanolic acid, a kind of hydroxy pentacyclic terpene, is the active ingredient of many natural plants, such as Eriobotrya japonica (loquata), Perilla frutescens, Staphyleaholocarpa and the like, and is also found in fruits such as apples or pears. It has pharmacological effects, such as anti- inflammatory, anticancer, anti-allergic, anti-depressant, antibacterial and antifungal effects, and particularly exhibits anti-inflammatory and skin irritation alleviating effects by stimulating the physiological activity of the skin. In addition, with respect to anti-aging functions, oleanolic acid stimulates the synthesis of procollagen important in collagen production, stimulates the synthesis of ceramide and filaggrin, which are important in aging prevention. Moreover, it has a dual anti- aging system which stimulates the production of collagen and prevents the destruction of collagen by inhibiting the activity of MMP-1 that is an enzyme destroying polymer proteins such as produced collagen. Oleanolic acid having excellent effects on the reduction in skin wrinkles as described above has been used as a raw material in various emulsion-type cosmetic formulations to reduce skin wrinkles, but is substantially insoluble in water, and the content of oleanolic acid in cosmetic products is limited due to problems associated with stability and unstable activity.
Particularly, because of this insoluble property, it is impossible to use oleanolic acid directly as a wrinkle reducing agent in solubilized formulations such as cosmetic lotion.
In recent years, it was reported that the stability of oleanolic acid can be increased by encapsulating oleanolic acid into nanoemulsions having a size of 100-150 nm using a skin lipid- like composition and nanotechnology and further encapsulating the oleanolic acid with a polymer emulsifier using the natural polysaccharide inulin and that the encapsulated oleanolic acid can be used in all types of cosmetic formulations. However, oleanolic acid encapsulated as described above should be introduced into emulsion-type formulations at a temperature of 50 °C or below and a low homomixing speed in order to prevent the capsules from being broken during the preparation process. Particularly, problems associated with the stability and unstable activity of oleanolic acid are still present in solubilized formulations. In addition, the use of encapsulated oleanolic acid is more expensive than the use of non-encapsulated oleanolic acid. Further, it can adversely affect the sensory feel of the product, because additional components other than oleanolic acid are used to encapsulate oleanolic acid.
Furthermore, the worldwide market size of certified organic cosmetic products is increasing, and only oleanolic acid is being recognized as a natural functional component for reducing wrinkles. However, when oleanolic acid is encapsulated using a skin lipid-like composition and nanotechnology as described above, it cannot be used as a certified organic cosmetic raw material, because it contains a large number of components which are not acceptable in certified organic cosmetic products.
The present invention has been made in order to solve the above-described problems occurring in the prior art, and an object of the present invention is to provide a solubilized cosmetic composition wherein oleanolic acid having an excellent effect of reducing wrinkles is stably encapsulated in nano-liposomes without using additional components other than oleanolic acid.
In order to accomplish the above object, the present invention provides a cosmetic composition containing, as an active ingredient, oleanolic acid encapsulated in nano-liposomes.
In the cosmetic composition according to the present invention, oleanolic acid effective in reducing skin wrinkles is stably encapsulated in nano-liposomes, and thus the transdermal absorption rate of oleanolic acid is increased by the nano-liposomes. Thus, the cosmetic composition of the present invention exhibits an excellent effect of reducing skin wrinkles by reducing stimulating collagen synthesis. Moreover, the production cost of the cosmetic composition can be reduced, because an additional raw material for stabilizing oleanolic acid is not used. In addition, the cosmetic composition of the present invention can provide a fresh and moist touch feel after absorption and can satisfy the consumer’s demand for certified organic anti-wrinkle functional cosmetic products, which is increasing worldwide.
The present invention provides a cosmetic composition containing oleanolic acid as an active ingredient, and the cosmetic composition may be formulated in a solubilized form. In the cosmetic composition, oleanolic acid is encapsulated in nano-liposomes and is stabilized by the nano-liposomes. Thus, the stability and solubility of oleanolic acid in the solubilized formulation can be increased, and the transdermal absorption rate thereof can be increased.
Oleanolic acid that is used in the present invention is an unique component recognized as a natural anti-wrinkle functional component. The cosmetic composition of the present invention contains oleanolic acid in an amount of 0.0001-5.0 wt%, and preferably 0.0005-1.0 wt%, based on the total weight of the composition. If the content of oleanolic acid in the composition is less than 0.0001 wt%, a distinct effect cannot be obtained, and if the content of oleanolic acid is more than 5.0 wt%, an increase in the content will not lead to a distinct increase in the anti-wrinkle effect and will adversely affect the stability of the formulation.
Nano-liposomes which are formed during the preparation of the solubilized cosmetic composition of the present invention refer to liposomes having an average particle diameter of 10- 500 nm. The nano-liposomes that are formed in the present invention preferably have a size of 50- 300 nm. If the average particle diameter of the nano-liposomes is more than 300 nm, improvements in skin penetration and formulation stability, among the technical effects to be achieved by the present invention, will be very insignificant.
The nano-liposomes that are formed to stabilize oleanolic acid in the present invention are prepared by a mixture containing a polyol, an oily component, a surfactant, a phospholipid, and water. Also, the nano-liposomes encapsulating oleanolic acid in the solubilized cosmetic composition are naturally formed during the preparation of the solubilized cosmetic composition without having to carry out high-pressure emulsification or a separate preparation process.
The polyol that is used in the inventive solubilized cosmetic composition containing the nano-liposomes is not specifically limited, but is preferably one or more selected from the group consisting of propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isopropylene glycol, pentylene glycol, erythritol, xylitol, sorbitol, and mixtures thereof. In addition, the polyol is used in an amount of 5-50 wt%, and preferably 15-30 wt%, based on the total weight of the solubilized cosmetic composition containing the nano-liposomes.
The oily component that is used in the inventive solubilized cosmetic composition containing the nano-liposomes may be selected from among various components known in the art.
Preferred examples of the oily component include hydrocarbon-based oils such as hexadecane and paraffin oil, ester-based synthetic oils, silicone oils such as dimethicone and cyclodimethicone, animal and plant oils such as sunflower oil, corn oil, soybean oil, avocado oil, sesame oil and fish oil, cthoxviated alkyl ether oil, propoxylated alkyl ether oil, sphingoid lipids such as phytosphingosine, sphingosine and sphinganine, cerebroside cholesterol, sitosterol cholesteryl sulfate, sitosterol sulfate, Coup fatty alcohols, and mixtures thereof. The content of the oily component in the solubilized cosmetic composition is 0.01-10.0 wt%, and preferably 1.0-5.0 wt%, based on the total weight of the solubilized cosmetic composition comprising the nano-liposomes.
The surfactant that is used in the solubilized cosmetic composition of the present invention may be any surfactant known in the art. Examples of the surfactant that is used in the present invention include anionic surfactants, cationic surfactants, amphoteric surfactants and nonionic surfactants. Preferably, anionic surfactants and nonionic surfactants may be used in the present invention. Specific examples of the anionic surfactants include atkyi acyl glutamate, alkyl phosphate, alkyl lactate, dialkyl phosphate and trialkyl phosphate. Specific examples of the non- ionic surfactants include polysorbate, alkoxylated alkyl ether, alkoxylated alkyl ester, alkyl polyglycoside, polvalyeeryl ester and sugar ester. The content of the surfactant in the solubilized cosmetic cornposition 1s 0.001-5.0 wt%, and preferably 0.1-1.0 wt%, based on the total weight of the solubilized cosmetic composition comprising the nano-liposomes.
A phospholipid in the nano-liposomes that are formed in the present invention is an amphoteric lipid, and examples thereof includes natural phospholipids (e.g., egg lecithin, soybean lecithin or sphingomyelin) and synthetic phospholipids (e.g., dipalmitoylphosphatidylcholine or hydrogenated lecithin), preferably lecithin. More preferably, the phospholipid is a naturally occurring saturated or unsaturated lecithin extracted from soybean or egg yolk. In general, the naturally occurring lecithin has a phosphatidylcholine content of 23-95% and a phosphatidylethanolamine content of 20% or less. The content of the phospholipid in the preparation of the inventive solubilized cosmetic composition containing the nano-liposomes is 0.01-5.0 wt%, and preferably 0.5-2.0 wt%, based on the total weight of the solubilized cosmetic composition.
Water in the inventive solubilized cosmetic composition containing the nano-liposomes is generally distilled water and is used in an amount of 25.0-90.0 wt% based on the total weight of the solubilized cosmetic composition.
The solubilized cosmetic composition of the present invention contains oleanolic acid, and thus can particularly be used as an anti-aging composition having an excellent effect of reducing skin wrinkles.
The formulation of the composition of the present invention is not specifically limited. In view of a transparent or suspended appearance and advantages in use, the composition of the present invention may be used as basic cosmetic compositions such as skin softener, nourishing lotion, spray, mist or gel, hair cosmetic compositions such as hair growth agents, including hair tonic, hair essence or hair treatment, and other medical drugs and quasi-drgs. In addition, it may also be used as a skin wrinkle-reducing agent, which shows an excellent effect and is safe without side effects when being applied to the hurnan skin.
The cosmetic composition according to the present invention may contain additives which are generally used in the cosmetic field or the skin science field, for example, fatty substance, organic solvent, solubilizing agent, thickener, gelling agent, softener, antioxidant, suspending agent, stabilizer, foaming agent, fragrance, surfactant, water, ionic or non-ionic emulsifying agent, filler, metal ion sequestering agent, metal ion chelating agent, preservative, vitamins, blocker,
wetting agent, essential oil, dye, pigment, hydrophilic or hydrophobic activator, lipid vesicle, or other components which are generally used in cosmetic products. These additives are introduced in amounts which are generally used in the cosmetic field or the skin science field.
Mode for Invention
Hereinafter, the present invention will be described in further detail with reference to examples and test examples. It is to be understood, however, that the following examples, test examples and preparation examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Reference Example 1: Preparation of solubilized cosmetic lotion containing oleanolic acid stabilized with nano-liposomes
According to the compositions shown in Table 1 below, wrinkle-reducing solubilized cosmetic lotions of Examples 1 to 3 and Comparative Example 1 to 4 were prepared.
Lotions of Examples 1 to 3 are solubilized cosmetic lotions containing nano-liposomes formed according to the present invention, and lotions of Comparative Examples 1 and 2 contain general solubilizing agents different from those of Examples 1 to 3, and lotion of Comparative
Example 3 contains an encapsulated oleanolic acid nanobase. Lotion of Comparative Example 4 is a lotion containing an oleanolic acid dissolved in a 4:1 mixture of ethanol and propylene glycol.
Table 1 (unit: wt%)
Component Exampl | Exampl | Exampl | Compa [Compa |Compa |Compa el e e3 rative |rative [rative |rative 2 Exampl | Exampl | Exampl | Exampl el e?2 e3 ed
Hydrogenated lecithin 005 [02 io | - Joa [
PEG-60 hydrogenated castoroil |- |- | [18 [J]. |- 3 |caprylic/capryl glucoside - Be 4 [Propylene glycol 5 |Glyeerin ~~ |400 400 [400 [400 [400 [400 |- 6 |Dicaprylyl carbonate as. [gs gs. gs. gs gs. [ [7_|Oleanolic acid 005 005 [00s [005 [005 |- [0.05
8 [Preservative gs. gs. gs. [gs [gs gs.
O |Fragmnce ~~ gs. gs. gs. [gs gs. Jgs 11 [Purifiedwater [balance |balance [balance [balance [balance [balance |-
Dermofeel PA-3 002 [002 002 [002 1002 002 [ 13 [Betaine ~~ [200 200 [200 [200 [200 [2.00 |- 14 Xanthangum ~~ Jo2 02 Joa [02 Joa [02 15 |Encapsulated oleanolic nanobase 25 (containing 0.05 wt% oleanolic acid)
The lotions were prepared in the following manner. 1) Components 1 to 3 and polyol components 4 to 5 were mixed and dissolved by heating to 80 °C, and then components 6 to 9 were added thereto and uniformly mixed. 2) The mixture of step 1) was cooled to 65 °C, and then ethanol (component 10) was added thereto and sufficiently mixed. 3) Aqueous part components 11 to 14 were mixed uniformly and heated to 65 °C, after which the mixture was uniformly mixed with the mixture of step 2). 4) The mixture of step 3) was cooled to room temperature and stored.
Meanwhile, in the preparation of the lotion of Comparative Example 3, an encapsulated oleanolic acid nanobase (component 15) was added after step 3).
Test Example 1: Evaluation of stability of composition
In order to evaluate the stability of the wrinkle-reducing cosmetic composition with time, the solubilized cosmetic lotions prepared in Examples 1 to 3 and Comparative Examples 1 to 4 were stored for 1 month in each of a room temperature incubator, a 45 °C incubator and an incubator that was circulated from -10 °C to 45 °C at 12-hr intervals, and then the changes in the appearances of the lotions were observed.
Table 2
Items |Kind of surfactant Average | Stability (solubilizing agent) par ticl e siz e (n m)
Room temperature e|45 °C Circulated temperature
Next (1 4 Next (1 4 Next (1 4 da |week [week | day |week [week | day |week [week y S S S
Examp|0.05% hydrogenated [376 good [good |Separ |good [Separ |Separ |good |good |Separ lel lecithin ated ated [ated ated
Examp|0.20% hydrogenated [257 good [good |good |good [good [good |good |good [good le2 [lecithin
Examp|1.00% hydrogenated [234 good [good |Preci |good [good |Preci |good |good |Preci le3 |lecithin pitate pitate pitate d d d
Comp [1.80% PEG-60 245 Separ Separ Separ arative | hydrogenated castor oil ated ated ated
Examp le 1
Comp |3.60% caprylic/capryl (241 Separ Separ Separ arative | glucoside ated ated ated
Examp le 2
Comp |0.20% hydrogenated (240 good [good |good |good [good |Separ|good |Separ arative | lecithin ated ated
Examp le 3
As can be seen from the results in Table 2 above, the lotions of Examples 1 to 3, which contain oleanolic acid encapsulated in nano-liposomes, were stable over a long period of time compared to the lotions of Comparative Examples 1 and 2, which contain other general solubilizing agents. Also, from the comparison between Example 2 and Comparative Examples 1 and 2, it can be seen that the amount of the surfactant used in Example 2 in which oleanolic acid was stabilized by encapsulation in nano-liposomes was significantly smaller than the amount of the surfactant used in Comparative Examples 1 and 2. This suggests that, when oleanolic acid is encapsulated in nano-liposomes formed, the amount of the surfactant to be used in the formulation can be significantly reduced, and the risk of skin irritation, which is caused by the use of a large amount of a surfactant, can be avoided.
Test Example 2: Comparison of sensory feeling between a composition containing oleanolic acid stabilized with nano-liposomes and a composition containing encapsulated oleanolic acid
In order to evaluate the sensory feelings of the compositions of Example 2 and
Comparative Example 3, a sensory test was performed for the wrinkle-reducing cosmetic compositions prepared in Example 2 and Comparative Example 3. Twenty 25-35 years old women were selected as subjects. Each of the cosmetic compositions was applied to the back of the hand of each subject according to a general method, and then the satisfaction of the sensory feeling of each composition was evaluated. The sensory evaluation of each composition was performed with respect to a total of 4 items, including stickiness, absorption feeling, moist feeling and nourishing feeling, on the basis of the following criteria: very superior (10), superior (7.5), moderate (5), inferior (2.5) and very inferior (0). The values of the evaluation were averaged and shown in Table 3 below.
Table 3 feeling 3
Absorption feeling [98 [52
Nourishing feeling [69 [63
From the comparison between the composition of Example 2, which contains oleanolic acid stabilized with nano-liposomes formed in the formulation, and the composition of
Comparative Example 3, which contains encapsulated oleanolic acid, it can be seen that, because the amount of the stabilizing agent used to prepared the encapsulated oleanolic acid nanobase in
Comparative Example 3 was larger by about 2.4 wt% than that in Example 2, the stabilizing agent in Comparative Example 3 had an adverse effect on the sensory feeling. Also, as can be seen in
Table 3 above, the sensory feeling of the formulation (Example 2) containing oleanolic acid stabilized with nano-liposomes formed therein is significantly excellent compared to the formulation of Comparative Example 3.
Test Example 3: Measurement of effect on stimulation of collagen biosynthesis
The effect of the composition of Example 2 on the stimulation of collagen biosynthesis was measured comparatively with those of tocopherol and EGCG, which are known to stimulate collagen biosynthesis. First, human fibroblasts (PromoCell, Germany) were seeded in a 24-well plate at a density of 10° cells and cultured to a confluence of about 90%. The cells were cultured in serum-free DMEM medium for 24 hours, and then treated with 10™ M of each of the composition of Example 2, tocopherol and EGCG in serum-free medium. Then, the cells were incubated in a
CO; incubator for 24 hours. The supernatant of each of the cell cultures was collected, and the amount of procollagen in the supernatant was measured using a procollagen type (I) ELISA kit.
The results of the measurement are shown in Table 4 below. In Table 4, the values of synthesis are expressed as percentages relative to the untreated group taken as 100.
Table 4 =
As can be seen in Table 4 above, the composition of Example 2 stimulates collagen biosynthesis and has a significantly better effect on the stimulation of collagen biosynthesis compared to tocopherol and EGCG, which are known to stimulate collagen biosynthesis.
Test Example 4: Measurement of absorption into skin
Absorption into the skin was measured on the skin of guinea pigs using Frantz permeation cells. Immediately before the experiment, abdominal skin of guinea pigs was collected and cut to a size of 1 cm, The cut skin was placed in a permeation cell having a permeation lens diameter of 0.9 cm and was fixed by a clamp. 0.2 g of each of the sample of Comparative Example 4, which contains a solution of oleanolic acid in ethanol and propylene glycol (4:1), and the sample of
Example 2, which contains oleanolic acid stabilized with nano-liposomes, was applied to one side of the skin (donor container), and the other side (receptor container) was brought into contact with a solvent consisting of a 4:1 mixture of purified water and ethanol. The temperature during the experiment was maintained at 32 °C (actual skin temperature). After the start of the experiment, a portion of the solvent was collected at intervals of a given time, and then the amount of oleanolic acid absorbed into the skin was measured by HPLC. The results of the measurement were expressed as skin absorption per applied concentration (48/CT/wt%) and are shown in Table 5 below.
HPLC analysis conditions - column: Waters Novapak C18 (3.9 mm * 250 mm, 4 um) - solvent flow rate: 1 M¢/min - detection UV: 210 nm - sample measurement concentration: 10-100 ug/mL - injected sample amount: 20 ull - eluent: MeOH/0.1% H3:PO4 = 82/18
Table 5 o oo jo 000000] s 000 [3613 00 85 00
As can be seen from the results in Table 5 above, the composition of Example 2, which contains oleanolic acid stabilized with nano-liposomes formed therein, showed a significantly large amount of transdermal absorption compared to that of Comparative Example 2.
Claims (7)
- I. A cosmetic composition containing, as an active ingredient, oleanolic acid encapsulated in nano-liposomes.
- 2. The cosmetic composition of claim 1, wherein the oleanolic acid is contained in an amount of 0.0001-5.0 wt% based on the total weight of the composition.
- 3. The cosmetic composition of claim 1, wherein the nano-liposomes having the oleanolic acid encapsulated therein is contained in an amount of 0.001-50 wt% based on the total weight of the composition.
- 4. The cosmetic composition of claim 1, wherein the nano-liposomes have an average particle diameter of 50-300 nm.
- 5. The cosmetic composition of claims 1 to 4, wherein the composition is a solubilized formulation.
- 6. The cosmetic composition of claim 1, wherein the composition is for anti-aging.
- 7. The cosmetic composition of claim 1, wherein the composition is for stimulating collagen biosynthesis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100116288A KR101821207B1 (en) | 2010-11-22 | 2010-11-22 | Solubilization cosmetic composition containing oleanolic acid |
PCT/KR2011/008785 WO2012070804A2 (en) | 2010-11-22 | 2011-11-17 | Cosmetic composition containing an oleanolic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
SG190131A1 true SG190131A1 (en) | 2013-06-28 |
Family
ID=46146254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013034087A SG190131A1 (en) | 2010-11-22 | 2011-11-17 | Cosmetic composition containing an oleanolic acid |
Country Status (6)
Country | Link |
---|---|
JP (2) | JP6321962B2 (en) |
KR (1) | KR101821207B1 (en) |
CN (1) | CN103221028B (en) |
HK (1) | HK1186963A1 (en) |
SG (1) | SG190131A1 (en) |
WO (1) | WO2012070804A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103830116B (en) * | 2014-03-26 | 2017-01-04 | 清华大学 | Ligustilide prevents purposes and the using method of skin photoage skin care item in preparation |
CN103830118A (en) * | 2014-03-26 | 2014-06-04 | 清华大学 | Application and use method of salidroside in preparing skin-care product for preventing skin photoaging |
JP6605794B2 (en) * | 2014-09-22 | 2019-11-13 | 株式会社ファンケル | Arginase 1 production promoter |
KR102621819B1 (en) * | 2015-03-02 | 2024-01-08 | (주)아모레퍼시픽 | Nano multilamella liposome containg skin lipid ingredient and manufacturing method thereof |
CN106309313A (en) * | 2016-08-24 | 2017-01-11 | 彭友莲 | Whitening facial cleanser and preparing method thereof |
KR20190079276A (en) * | 2017-12-27 | 2019-07-05 | 정한수 | Anti-aging cosmetics with nanoparticles-ingredient that solubilized insoluble oligoanionic acid and manufacturing method for anti-aging cosmetics |
CN108403751B (en) * | 2018-05-23 | 2021-04-06 | 阜阳师范学院 | Application of triterpenoid saponin in trichosanthes peel |
KR20210120633A (en) | 2020-03-27 | 2021-10-07 | (주)아모레퍼시픽 | Sheet type mask gel composition, mask sheet comprising the same and manufacturing method of mask sheet |
CN113413325B (en) * | 2021-05-31 | 2022-04-05 | 宝萃生物科技有限公司 | Lip plumping composition and preparation method and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100489701B1 (en) * | 2002-10-09 | 2005-05-16 | 주식회사 태평양 | Submicron-liposome containing highly concentrated triterpenoid and method for preparing thereof |
KR100654846B1 (en) * | 2004-12-02 | 2006-12-06 | 한국콜마 주식회사 | Cosmetic composition comprising nano size liposome and oil in water type emulsion and manufacturing method thereof |
KR20060087817A (en) * | 2005-01-31 | 2006-08-03 | 주식회사 태평양 | Anti-aging cosmetic composition |
KR100654841B1 (en) * | 2005-06-27 | 2006-12-06 | 한국콜마 주식회사 | Lipid solution composition and method for preparing nano particle cosmetics having analogous structure and composition of human skin and promoting the transepidermal absorption of physiologically active substances using the same |
WO2007078060A1 (en) * | 2005-12-30 | 2007-07-12 | Amorepacific Corporation | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same |
JP2007224012A (en) * | 2006-01-30 | 2007-09-06 | Fujifilm Corp | Enzymatically crosslinked protein nanoparticle |
ES2286953B1 (en) * | 2006-05-18 | 2008-12-16 | Universidad De Granada | FORMULATION OF NATURAL TRITERPENES AND BIOPHENOLS OBTAINED FROM THE OLEA GENDER IN LIPOSOMAS. |
CN1923178A (en) * | 2006-08-22 | 2007-03-07 | 河南大学 | Oleanolic acid liposome preparation, freeze dried powder injecta thereof and its preparation |
KR20080038812A (en) * | 2006-10-31 | 2008-05-07 | (주)아모레퍼시픽 | A cosmetic of sheet-type containing unsoluble material stably in a low viscosity level state |
KR100792629B1 (en) * | 2006-11-20 | 2008-01-09 | (주)아모레퍼시픽 | Skin whitening cosmetic composition containing oldenlandia diffusa extract stabilized with nano-liposome |
JP2008297241A (en) * | 2007-05-31 | 2008-12-11 | Fujifilm Corp | Anti-acne skin agent for external use |
CN101843623B (en) * | 2010-04-09 | 2012-03-14 | 澳门理工学院 | External fat-increasing preparation and application thereof |
CN101923178B (en) | 2010-08-16 | 2012-05-23 | 中国海洋石油总公司 | Sub-pixel matching-based towline dynamic acquisition influence eliminating method |
-
2010
- 2010-11-22 KR KR1020100116288A patent/KR101821207B1/en active IP Right Grant
-
2011
- 2011-11-17 CN CN201180055817.3A patent/CN103221028B/en active Active
- 2011-11-17 SG SG2013034087A patent/SG190131A1/en unknown
- 2011-11-17 WO PCT/KR2011/008785 patent/WO2012070804A2/en active Application Filing
- 2011-11-17 JP JP2013539759A patent/JP6321962B2/en active Active
-
2013
- 2013-12-30 HK HK13114369.9A patent/HK1186963A1/en unknown
-
2016
- 2016-07-22 JP JP2016144525A patent/JP6231624B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20120054906A (en) | 2012-05-31 |
WO2012070804A2 (en) | 2012-05-31 |
JP6321962B2 (en) | 2018-05-09 |
WO2012070804A3 (en) | 2012-07-19 |
JP2013542984A (en) | 2013-11-28 |
KR101821207B1 (en) | 2018-01-24 |
CN103221028B (en) | 2016-04-20 |
HK1186963A1 (en) | 2014-03-28 |
JP6231624B2 (en) | 2017-11-15 |
CN103221028A (en) | 2013-07-24 |
JP2016222694A (en) | 2016-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG190131A1 (en) | Cosmetic composition containing an oleanolic acid | |
KR20070081192A (en) | Cosmetic compostion comprising liposome incorporating oryzanol, rice bran oil and phospholipid | |
KR20130023912A (en) | Peptides stabilized using liposome and cosmeceutical composition thereof | |
KR20180027375A (en) | Compositions for Moisturizing Skin Containing Vegetable Vernix Ingredients | |
KR101595530B1 (en) | Liposome composition having excellent effect of skin wrinkle improvement and skin whitening for accelerating percutaneous absorption | |
KR102078667B1 (en) | Cosmetic composition containg nanoemulsion encapsulated with 7-dehydrocholesterol, cholesterol and stearic acid in inner phase of hyaluronate-ceramide NP complex and manufacturing method thereof | |
KR20040101588A (en) | Cosmetic Compostion for Preventing Skin Aging Comprising Plant Extract as Oriental Medicine Stabilized in Nanoliposome | |
KR20150077214A (en) | Liquid crystal cosmetic composition having similar skin lipid composition and containing glucosylceramide, and preparation method thereof | |
KR101862039B1 (en) | A cosmetic composition containing spicule powder and natural complex extract stabilized in nanoliposome | |
KR101325553B1 (en) | Cosmetic Composition for Protecting Skin Comprising Aminolevulinic acid Contained in Liquid Crystal Base | |
WO2015147137A1 (en) | Ceramide-formulated external agent composition | |
KR101549624B1 (en) | Temperature Sensitive Cosmetic Composition | |
KR20110078955A (en) | Cosmetic composition comprising moisture quality component as active ingredient | |
KR100858628B1 (en) | Cosmetic Composition for alleviating Skin Irritation Comprising Rumex Crispus L. Extract Stabilized in Nanoliposome | |
KR100681703B1 (en) | Cosmetic composition for enhancement of skin luster comprising the mixed extract of panax ginseng, sohizophyllum commune and phellodendron amurense ruprecht stabilized in nanoliposome | |
KR100888752B1 (en) | External dermal agent | |
KR20120037639A (en) | Capsulation method and cosmetic containing this capsulation for maximizing efficacy of sodium polygamma glutamate | |
KR100858626B1 (en) | Cosmetic Composition for Protecting lip Comprising Ceramide and Synthetic Palmitoylpentapeptide as an Active Ingredient | |
JP4592347B2 (en) | External preparation composition | |
KR20150078137A (en) | Cosmetic composition for improving skin wrinkle | |
JP2004051561A (en) | Skin cosmetic composition | |
EP2745835B1 (en) | Novel vesicle for topical application in pharmacy and cosmetics | |
JP5329489B2 (en) | External preparation composition | |
CN110652460B (en) | Compositions containing linoleic acid | |
KR20130057634A (en) | Method of stabilizing egcg and composition for whitening skin containing egcg |